BackOyster Point Pharma Overview

Oyster Point Pharma Total Current Liabilities

Track Oyster Point Pharma's total current liabilities ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$29.20M
92.58% YoYΔ $14.04M vs prior year quarter

Peer trimmed avg / median

Loading

Oyster Point Pharma Total Current Liabilities History

Loading

Oyster Point Pharma vs. peers: Total Current Liabilities Comparison

Loading

Oyster Point Pharma Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Oyster Point Pharma (OYST) FAQ

Oyster Point Pharma posts a total current liabilities of $29M as of September 2022. That compares with $15M in the prior-year period — up 92.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Oyster Point Pharma's total current liabilities was $15M. The latest reading is $29M — a 92.6% year-over-year increase (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of Oyster Point Pharma's financial statement story. At $29M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for OYST's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Oyster Point Pharma's other metric pages and overview cover the third.

Judging Oyster Point Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $29M here, then scan peer and history charts to see if the gap is persistent.